<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140211">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275664</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0272</org_study_id>
    <secondary_id>NCI-2011-02660</secondary_id>
    <secondary_id>CDR0000692516</secondary_id>
    <secondary_id>GOG-0272</secondary_id>
    <secondary_id>GOG-0272</secondary_id>
    <secondary_id>GOG-0272</secondary_id>
    <secondary_id>U10CA101165</secondary_id>
    <nct_id>NCT01275664</nct_id>
  </id_info>
  <brief_title>Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer</brief_title>
  <official_title>Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in
      preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III,
      or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen
      or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III,
      or stage IV ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the frequency of chemotherapy-induced nausea and vomiting based on complete
      response (no vomiting and no use of rescue therapy) during the 6 days following
      intraperitoneal (IP) chemotherapy for the 3-day regimen of aprepitant (both injection and
      capsules) in combination with granisetron transdermal system and dexamethasone in ovarian
      cancer patients receiving IP cisplatin OR IP carboplatin.

      SECONDARY OBJECTIVES:

      I. To evaluate possible endpoints for the chemotherapy-induced nausea and vomiting,
      including:

        -  Functional Living Index-Emesis (FLIE) questionnaire scores

        -  Mean vomiting, nausea and total FLIE scores and changes from baseline in FLIE scores

        -  Percentages of patients with no impact on daily living (NIDL), i.e. &gt; 108/126 total
           FLIE score II. To describe the timing of nausea and vomiting that may guide
           modifications to the standard regimen.

      OUTLINE: This is a multicenter study.

      Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0
      (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive
      dexamethasone orally (PO) on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes
      before IP platinum therapy), and aprepitant PO on days 2-3.

      Patients complete the Functional Living Index--Emesis (FLIE) and a symptom diary at baseline
      and on days 3 and 6.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily Closed to Accrual
  </why_stopped>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of complete control defined as no vomiting and no use of rescue medications (for nausea or emesis) based on the patient-completed symptom diary</measure>
    <time_frame>During the 6 days following chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vomiting, nausea and total FLIE scores</measure>
    <time_frame>Baseline to day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse effects as assessed by the NCI CTCAE v 4.0</measure>
    <time_frame>Up to day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and standard deviation of vomiting, nausea, and total FLIE scores</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of patients with NIDL based on FLIE</measure>
    <time_frame>Up to day 6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Malignant Ovarian Mixed Epithelial Tumor</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Ovarian Brenner Tumor</condition>
  <condition>Ovarian Clear Cell Cystadenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Mucinous Cystadenocarcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Stage II Ovarian Cancer</condition>
  <condition>Stage IIA Fallopian Tube Cancer</condition>
  <condition>Stage IIA Ovarian Cancer</condition>
  <condition>Stage IIB Fallopian Tube Cancer</condition>
  <condition>Stage IIB Ovarian Cancer</condition>
  <condition>Stage IIC Fallopian Tube Cancer</condition>
  <condition>Stage IIC Ovarian Cancer</condition>
  <condition>Stage IIIA Fallopian Tube Cancer</condition>
  <condition>Stage IIIA Ovarian Cancer</condition>
  <condition>Stage IIIA Primary Peritoneal Cancer</condition>
  <condition>Stage IIIB Fallopian Tube Cancer</condition>
  <condition>Stage IIIB Ovarian Cancer</condition>
  <condition>Stage IIIB Primary Peritoneal Cancer</condition>
  <condition>Stage IIIC Fallopian Tube Cancer</condition>
  <condition>Stage IIIC Ovarian Cancer</condition>
  <condition>Stage IIIC Primary Peritoneal Cancer</condition>
  <condition>Stage IV Fallopian Tube Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Stage IV Primary Peritoneal Cancer</condition>
  <condition>Undifferentiated Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adjuvant Therapy</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>adjunct therapy</other_name>
    <other_name>adjunctive therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Emend</other_name>
    <other_name>L-754030</other_name>
    <other_name>MK-0869</other_name>
    <other_name>ONO-7436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IP</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IP</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron Transdermal Patch</intervention_name>
    <description>Apply one patch to upper arm</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
    <other_name>Granisetron Transdermal System</other_name>
    <other_name>Sancuso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Management of Therapy Complications</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (granisetron, dexamethasone, aprepitant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal carcinoma

               -  Stage II, III, or IV disease with optimal (=&lt; 1 cm residual disease) or
                  suboptimal residual disease

               -  All patients must have a procedure for determining diagnosis of epithelial
                  ovarian, fallopian tube, primary peritoneal, with appropriate tissue for
                  histologic evaluation

               -  The minimum surgery required is an abdominal surgery providing tissue for
                  histologic evaluation and establishing and documenting the primary site and
                  stage, as well as a maximal effort at tumor debulking; if additional surgery was
                  performed, it should have been in accordance with appropriate surgery for
                  ovarian or peritoneal carcinoma described in the Gynecologic Oncology Group
                  (GOG) Surgical Procedures Manual

          -  Patients with the following histologic epithelial cell types are eligible:

               -  Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,
                  undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial
                  carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or
                  adenocarcinoma not otherwise specified (N.O.S.)

               -  However, the histologic features of the tumor must be compatible with a primary
                  MÃ¼llerian epithelial adenocarcinoma; if doubt exists, it is recommended that the
                  investigator should have the slides reviewed by an independent pathologist prior
                  to entry

               -  Patients may have co-existing endometrial cancer so long as the primary origin
                  of invasive tumor is ovarian or peritoneal for clarification of synchronous
                  primary endometrial cancer

          -  Patients receiving the initial course of chemotherapy including

               -  Paclitaxel 135 mg/M2 IV over 3 hours on day 1 and

               -  Cisplatin 75 mg/M2 IP on day 2 OR

               -  Paclitaxel 80 mg/m2 IV days 1, 8 and 15 and

               -  Carboplatin AUC 6 IP on day 1

          -  Prothrombin time (PT) such that international normalized ratio (INR) is &lt; 1.5 x ULN
             (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of
             therapeutic warfarin)

          -  Partial thromboplastin time (PTT) &lt; 1.5 times the upper limit of normal (heparin,
             lovenox or alternative anticoagulants are acceptable)

          -  Patients with a GOG Performance Status of 0, 1, or 2

          -  Patients who are able to read, understand and write English; if FLIE which has been
             translated into other languages, and validated, becomes available, then patients
             speaking these languages can be enrolled if translation of the symptom diary can be
             arranged dependent on availability of suitable translators

          -  Patients who are able to complete the assessments

          -  Patients who are able to comply with the anti-emetic therapy

          -  Patients must have met pre-entry requirements

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

        Exclusion Criteria:

          -  Patients who are known to be hypersensitive to aprepitant, granisetron or any of the
             components of the patch or to dexamethasone

          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity
             or pelvis are excluded; prior radiation for localized cancer of the breast, head and
             neck, or skin is permitted, provided that it was completed more than three years
             prior to registration, and the patient remains free of recurrent or metastatic
             disease

          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor
             including neo-adjuvant chemotherapy for their ovarian or primary peritoneal cancer
             are excluded; patients may have received prior adjuvant chemotherapy for localized
             breast cancer, provided that it was completed more than three years prior to
             registration, and that the patient remains free of recurrent or metastatic disease

          -  Patients who are pregnant or nursing; to date, no fetal studies in animals or humans
             have been performed; the possibility of harm to a fetus is likely

          -  Patients with clinical symptoms or signs of gastrointestinal obstruction and/ or
             those who require parenteral hydration and/or nutrition; patients with history or
             current diagnosis of inflammatory bowel disease are not eligible

          -  Patients with medical history or conditions not otherwise previously specified which
             in the opinion of the investigator should exclude participation in this study;
             examples of this would be hearing loss or neuropathy which would prevent tolerance to
             cisplatin, and paclitaxel administration; the investigator should feel free to
             consult the Study Chair or Study Co-Chairs for uncertainty in this regard

          -  Patients who, in the opinion of the treating physician, have a medical condition, or
             currently take medications, which are felt to contraindicate safe or effective
             administration of the standard three drug anti-emetic regimen used in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Plaxe</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sudarshan K Sharma MD Limted-Gynecologic Oncology</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 16, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Brenner Tumor</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Cystadenocarcinoma, Mucinous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
